1. India Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
Medico Intercontinental Ltd.

Medico Intercontinental Ltd.

BBSE:MIL
23.42
INR
-0.27
(-1.14%)
-12.52EPS
296.45MMarket Cap
Medico Intercontinental Ltd.
BSE:MIL
(Bombay Stock Exchange)

Recent

price

23.42

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
- -
- -
- -
0.8
0.84
0.3
6.24
1.2
30.63
252.27
214.65
228.55
118.54
71.36
95.32
84.08
83.36
Revenue per Share
-0.01
- -
-0.08
0.48
0.01
-0.19
0.03
0.09
2.27
7.25
7.93
9.54
5.61
3.95
5.06
-3.2
-5.4
Basic EPS, GAAP
- -
- -
- -
-0.08
-9.12
0.37
-0.16
0.81
2.86
-53.95
15.42
11.2
-16.37
4.34
-8.19
12.43
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.1
- -
- -
- -
Dividend per Share
11.05
11.05
10.97
11.44
10.12
9.93
9.97
10.06
12.32
19.58
29.35
38.89
41.19
45.03
50.09
46.89
- -
Book Value per Share
11.05
11.05
10.97
11.44
10.12
9.93
9.97
10.06
12.32
17.9
25.84
35.38
40.05
43.9
48.96
32.7
- -
Tangible Book Value per Share
- -
- -
- -
- -
3
3
3
3
3
3
3
3
6
10
10
10
10
Basic Weighted Avg Shares
- -
- -
- -
- -
3
1
20
4
100
820
697
743
762
714
953
841
834
Sales/Revenue/Turnover
- -
- -
- -
88.33
0.56
-227.44
3.24
11.9
7.01
5.38
6.75
6.47
6.72
7.86
7.8
-2.93
-5.28
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
2
2
3
8
54
60
Depreciation Expense
- -
- -
- -
- -
- -
-1
- -
- -
7
24
26
31
36
39
51
-32
-54
Net Income, GAAP
- -
- -
- -
32.8
- -
- -
10.64
36.34
26.83
26.39
27.07
26.73
27.02
27.42
27.35
- -
- -
Effective Tax Rate (%)
- -
- -
- -
59.43
1.01
-61.99
0.55
7.58
7.39
2.88
3.69
4.17
4.73
5.53
5.31
-3.81
-6.48
Profit Margin (%)
1
3
3
3
33
3
21
9
33
174
136
152
343
295
423
235
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
1
131
65
62
22
19
135
461
- -
LT Debt
3
3
3
3
33
32
32
33
40
64
95
126
412
450
501
323
- -
Total Equity
- -
- -
- -
3.93
- -
- -
0.32
0.87
13.78
26.33
17.1
16.94
10.74
8.23
9.05
- -
- -
Return on Invested Capital (%)
- -
- -
- -
3.93
- -
- -
0.32
0.87
20
26.04
18.02
18.57
12.05
8.97
9.85
- -
- -
Return on Capital (%)
-0.06
-0.02
-0.73
4.26
0.15
-1.87
0.35
0.91
20.24
45.48
32.41
27.96
13.41
9.16
10.63
-6.6
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
211
- -
LT Borrowings
- -
461
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
400
255
296

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
612
- -
Cash, Cash Equivalents & STI
- -
60
- -
Accounts Receivable, Net
- -
274
- -
Inventories
- -
149
- -
Total Current Liabilities
- -
377
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
211
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.6%
48.69%
-35.58%
Free Cash Flow
-372.86%
-219.67%
-251.89%
Net Income, GAAP
258.34%
-17.81%
-163.29%
Sales/Revenue/Turnover
507.93%
4.91%
-11.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
193
364
184
212
953
2026
214
204
198
225
841
2027
207
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.08
1.63
1.17
1.17
5.06
2026
-0.68
-1.65
-1.65
-0.65
-3.2
2027
-1.45
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
Medico Intercontinental Limited engages in the trading of pharmaceutical products in India. The company offers a broad portfolio of products across categories including gastro such as ACIFACT-BLI, ACIFACT-P, ACIFACT-SP, BALOFACT, CYCLOFACT 400, UDIFACT 150 and ZIFT SL-250; uro; nutrition such as ARGIFACT, CLIANCIACT POWDER and ZYMIX; cosmetology such as CAMBOGIA, LUBRIACT, HIZEN and CALAMED LOTION; health devices; hospital-related products; and other areas encompassing general and derma range items in forms including tablets, soft gelatine capsules, ointments, powders, sprays, liquids, ayurvedics, injectables, dry syrups, suspensions, drops, infusions, soaps and nutritional supplements, as well as medical FTF products like antiseptic liquids, multipurpose cleaners, hand washes, immunity boosters, N95 face masks, hand sanitizers and eye drops. It provides a platform for research-based biopharmaceutical companies to distribute novel and innovative therapies globally, with operations focused on the Indian market. Founded in 1984 and headquartered in Ahmedabad, India, the company, formerly known as Intercontinental Leasing & Finance Company Limited, changed its name in December 2018 to reflect its shift from leasing and finance to pharmaceuticals. Subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited and Azillian Healthcare Private Limited, which it completed acquiring in August for INR 35.42 million. In April 2024, Medico Intercontinental proposed incorporating a joint venture partnership firm to expand its strategic initiatives.